238 related articles for article (PubMed ID: 20473158)
1. Proinflammatory cytokines underlying the inflammation of Crohn's disease.
Strober W; Zhang F; Kitani A; Fuss I; Fichtner-Feigl S
Curr Opin Gastroenterol; 2010 Jul; 26(4):310-7. PubMed ID: 20473158
[TBL] [Abstract][Full Text] [Related]
2. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.
Brand S
Gut; 2009 Aug; 58(8):1152-67. PubMed ID: 19592695
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
4. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease.
Shen W; Durum SK
Neurochem Res; 2010 Jun; 35(6):940-6. PubMed ID: 19915978
[TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.
Colpaert S; Vastraelen K; Liu Z; Maerten P; Shen C; Penninckx F; Geboes K; Rutgeerts P; Ceuppens JL
Eur Cytokine Netw; 2002; 13(4):431-7. PubMed ID: 12517728
[TBL] [Abstract][Full Text] [Related]
6. Role of the IL-23/IL-17 axis in Crohn's disease.
Siakavellas SI; Bamias G
Discov Med; 2012 Oct; 14(77):253-62. PubMed ID: 23114581
[TBL] [Abstract][Full Text] [Related]
7. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.
Strober W; Fuss IJ
Gastroenterology; 2011 May; 140(6):1756-1767. PubMed ID: 21530742
[TBL] [Abstract][Full Text] [Related]
8. Role of the IL23/IL17 Pathway in Crohn's Disease.
Schmitt H; Neurath MF; Atreya R
Front Immunol; 2021; 12():622934. PubMed ID: 33859636
[TBL] [Abstract][Full Text] [Related]
9. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
Fuss IJ; Becker C; Yang Z; Groden C; Hornung RL; Heller F; Neurath MF; Strober W; Mannon PJ
Inflamm Bowel Dis; 2006 Jan; 12(1):9-15. PubMed ID: 16374252
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
Aggeletopoulou I; Assimakopoulos SF; Konstantakis C; Triantos C
World J Gastroenterol; 2018 Sep; 24(36):4093-4103. PubMed ID: 30271076
[TBL] [Abstract][Full Text] [Related]
11. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.
Kugathasan S; Saubermann LJ; Smith L; Kou D; Itoh J; Binion DG; Levine AD; Blumberg RS; Fiocchi C
Gut; 2007 Dec; 56(12):1696-705. PubMed ID: 17682002
[TBL] [Abstract][Full Text] [Related]
12. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.
Dambacher J; Beigel F; Zitzmann K; De Toni EN; Göke B; Diepolder HM; Auernhammer CJ; Brand S
Gut; 2009 Sep; 58(9):1207-17. PubMed ID: 18483078
[TBL] [Abstract][Full Text] [Related]
13. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease.
Kamada N; Hisamatsu T; Honda H; Kobayashi T; Chinen H; Takayama T; Kitazume MT; Okamoto S; Koganei K; Sugita A; Kanai T; Hibi T
Inflamm Bowel Dis; 2010 Apr; 16(4):568-75. PubMed ID: 19834969
[TBL] [Abstract][Full Text] [Related]
14. Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity.
Saeed MA; Ng GZ; Däbritz J; Wagner J; Judd L; Han JX; Dhar P; Kirkwood CD; Sutton P
Inflamm Bowel Dis; 2017 Apr; 23(4):593-602. PubMed ID: 28296821
[TBL] [Abstract][Full Text] [Related]
15. Immune system alterations in patients with inflammatory bowel disease during remission.
Sventoraityte J; Zvirbliene A; Kiudelis G; Zalinkevicius R; Zvirbliene A; Praskevicius A; Kupcinskas L; Tamosiūnas V
Medicina (Kaunas); 2008; 44(1):27-33. PubMed ID: 18277086
[TBL] [Abstract][Full Text] [Related]
16. Distinct profiles of effector cytokines mark the different phases of Crohn's disease.
Zorzi F; Monteleone I; Sarra M; Calabrese E; Marafini I; Cretella M; Sedda S; Biancone L; Pallone F; Monteleone G
PLoS One; 2013; 8(1):e54562. PubMed ID: 23349929
[TBL] [Abstract][Full Text] [Related]
17. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis.
Wang X; Zheng XY; Ma C; Wang XK; Wu J; Adem A; Zhu J; Zhang HL
Scand J Immunol; 2014 Sep; 80(3):180-90. PubMed ID: 24910360
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-12 antibody for active Crohn's disease.
Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
[TBL] [Abstract][Full Text] [Related]
19. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients.
Veny M; Esteller M; Ricart E; Piqué JM; Panés J; Salas A
Aliment Pharmacol Ther; 2010 Mar; 31(5):561-72. PubMed ID: 19958311
[TBL] [Abstract][Full Text] [Related]
20. Targeting Specific Immunologic Pathways in Crohn's Disease.
Ramos GP; Faubion WA; Papadakis KA
Gastroenterol Clin North Am; 2017 Sep; 46(3):577-588. PubMed ID: 28838416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
